DR1: A Drug Target / Disease Biomarker (G1810)

Target Name: DR1

NCBI ID: G1810

Content of Review Report on DR1 Target / Biomarker

DR1

DR1: A Drug Target / Disease Biomarker

DR1, also known as DR1 cell surface antigen, is a protein that is expressed on the surface of many different types of cells in the body. It is a glycoprotein with a molecular weight of approximately 180 kDa and is composed of two chains: a heavy chain and a light chain. The heavy chain consists of 114 amino acids and the light chain consists of 198 amino acids.

DR1 is a protein that is involved in many different processes in the body, including the immune response, inflammation, and tissue repair. It is a key player in the development and maintenance of tissues, including the skin, hair, nails, and bones. It is also involved in the regulation of cell growth and differentiation, as well as in the development and maintenance of cancer.

One of the most promising aspects of DR1 is its potential as a drug target. Because DR1 is involved in many different processes in the body, it is a potential target for a wide range of therapies. For example, DR1 has been shown to be involved in the development and progression of many different types of cancer, including breast, ovarian, and prostate cancer. It is also involved in the regulation of inflammation, which could make it a potential target for therapies that are designed to reduce inflammation.

In addition to its potential as a drug target, DR1 is also a potential biomarker. Because it is expressed in many different types of cells in the body, it is a potential indicator of the presence of certain diseases or conditions. For example, high levels of DR1 have been shown to be associated with the development of certain types of cancer, as well as with the development of certain autoimmune diseases.

Furthermore, DR1 is a good candidate for a diagnostic marker, as its expression is known to be associated with various diseases, including cancer, autoimmune diseases, and skin diseases.

DR1 has also been used in the development of some monoclonal antibodies (MAbs), which are laboratory-produced antibodies that can be used to detect and treat a wide range of diseases. These antibodies are produced by using a laboratory technique called clonal selection to isolate a single cell from a population of cells and then growing that cell in a lab to produce a large amount of antibodies. Because they are produced by a single cell, these antibodies are highly specific and have a high potential for minimal adverse effects.

DR1 has also been used in the development of adoptive cell transfer (ACT) strategies for cancer treatment. In ACT, cancer cells are taken from the patient, modified in the laboratory to express a specific type of immune receptor called a monoclonal antibody, and then returned to the patient's body. This allows the patient's body to recognize the cancer cells as foreign and destroy them.

In conclusion, DR1 is a protein that is expressed in many different types of cells in the body and is involved in many different processes in the body. Its potential as a drug target and biomarker make it an attractive target for research and development of new therapies.

Protein Name: Down-regulator Of Transcription 1

Functions: The association of the DR1/DRAP1 heterodimer with TBP results in a functional repression of both activated and basal transcription of class II genes. This interaction precludes the formation of a transcription-competent complex by inhibiting the association of TFIIA and/or TFIIB with TBP. Can bind to DNA on its own. Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4

The "DR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets